Immunitybio Ownership
| IBRX Stock | USD 2.81 0.10 3.44% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 698 M | Current Value 734.5 M | Avarage Shares Outstanding 362.1 M | Quarterly Volatility 168 M |
Immunitybio |
Immunitybio Stock Ownership Analysis
About 63.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.62. Immunitybio had not issued any dividends in recent years. ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. To learn more about Immunitybio call Richard Adcock at 844 696 5235 or check out https://immunitybio.com.Besides selling stocks to institutional investors, Immunitybio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immunitybio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immunitybio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Immunitybio Quarterly Liabilities And Stockholders Equity |
|
Immunitybio Insider Trades History
About 63.0% of Immunitybio are currently held by insiders. Unlike Immunitybio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immunitybio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Immunitybio's insider trades
Immunitybio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunitybio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunitybio backward and forwards among themselves. Immunitybio's institutional investor refers to the entity that pools money to purchase Immunitybio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perceptive Advisors Llc | 2024-12-31 | 1.2 M | Goldman Sachs Group Inc | 2024-12-31 | 1.1 M | Altium Capital Management, Lp | 2024-12-31 | 1.1 M | Jpmorgan Chase & Co | 2024-12-31 | 1 M | Bsc Private Wealth Management, Llc | 2024-12-31 | 846.4 K | Allen Holding Inc | 2024-12-31 | 687.6 K | Sheets Smith Wealth Management | 2024-12-31 | 634 K | Susquehanna International Group, Llp | 2024-12-31 | 563.9 K | Accurate Wealth Management, Llc | 2024-12-31 | 560 K | Vanguard Group Inc | 2024-12-31 | 17.3 M | Blackrock Inc | 2024-12-31 | 13.6 M |
Immunitybio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunitybio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunitybio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunitybio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunitybio Outstanding Bonds
Immunitybio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunitybio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunitybio bonds can be classified according to their maturity, which is the date when Immunitybio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Immunitybio Corporate Filings
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 25th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of December 2024 Other Reports | ViewVerify | |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.